Showing 1541-1550 of 2101 results for "".
- FDA Clears Cutera truFlex® for Muscle Rehab, Recovery, and Post-Surgical Usehttps://modernaesthetics.com/news/fda-clears-cutera-truflex-for-muscle-rehab-recovery-and-post-surgical-use/2485023/Cutera, Inc. has announced that its truFlex® muscle stimulation system has received expanded US Food and Drug Administration (FDA) clearances for use in rehabilitation, recovery, and muscle wellness applications. Originally cleared for aesthetic body contouring, the system can now be used to stre
- AAFPRS Issues Alert Regarding Rise of Counterfeit Neuromodulatorshttps://modernaesthetics.com/news/aafprs-issues-alert-regarding-rise-of-counterfeit-neuromodulators/2484932/The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has released a warning to consumers to remain vigilant as counterfeit and unapproved neuromodulators continue to enter the aesthetic medicine market. The AAFPRS issued the warning after the US Food and Drug Administration
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://modernaesthetics.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- RVL Pharmaceuticals Announces New CEO, Chief Growth Officerhttps://modernaesthetics.com/news/rvl-pharmaceuticals-announces-new-ceo-chief-growth-officer/2484615/RVL Pharmaceuticals, Inc. has appointed Lori Deo as Chief Executive Officer and Amy Shah as Chief Growth Officer, signaling a strategic leadership shift aimed at accelerating growth for its lead product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%. Deo, who previously se
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://modernaesthetics.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Skin of Color Society Media Day Analyzes Latest Trendshttps://modernaesthetics.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- Beauty Rep Launches Digital Platform to Modernize Brand-Practice Collaborationhttps://modernaesthetics.com/news/beauty-rep-launches-digital-platform-to-modernize-brand-practice-collaboration/2484439/A new digital platform, Beauty Rep, has launched to streamline the way aesthetic brands and practices collaborate, aiming to reduce operational inefficiencies in sales, marketing, and education. Founded by aesthetics industry veterans, Beauty Rep provides a centralized hub for brand-practi
- AAFPRS Forecasts Regeneration, Precision, and Personalization as Defining Aesthetic Trends for 2026https://modernaesthetics.com/news/aafprs-forecasts-regeneration-precision-and-personalization-as-defining-aesthetic-trends-for-2026/2484425/Aesthetic medicine is rapidly evolving beyond enhancement and rejuvenation, moving toward regenerative, precision-driven care tailored to the individual. The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has released its annual aesthetic trend forecast, highlighting the t
- VISTA Trial Validates Noninvasive Tool for Skin Feature Identificationhttps://modernaesthetics.com/news/vista-trial-validates-noninvasive-tool-for-skin-feature-identification/2484391/A novel imaging system may offer dermatologists a noninvasive alternative to assess histologic skin features, according to results from the VISTA Trial published in JAMA Dermatology. The multisite trial evaluated Enspectra Health’s VIO handheld cross-modal imaging system, which in
- FDA Warns Websites Selling Unapproved Botulinum Toxin Productshttps://modernaesthetics.com/news/fda-warns-websites-selling-unapproved-botulinum-toxin-products/2484341/The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including sym